Evidence map›Paper›PMID 40963786›Full record

ArticleOncoTargets and therapy2025

Can Epithelial-Myoepithelial Carcinoma of the Breast Benefit from TROP2 Antibody-Drug Conjugate?

Qing Zhao, Xiao Luo, Hua Xing, Chengwei Jiang, Jingchao Ma, Lu Tang

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in OncoTargets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Qing Zhao *Department of Breast Surgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, People's Republic of China.
Xiao Luo *Department of Breast Surgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, People's Republic of China.
Hua XingDepartment of Breast Surgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, People's Republic of China.
Chengwei JiangDepartment of Pathology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, People's Republic of China.
Jingchao MaDepartment of Pathology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, People's Republic of China.
Lu TangDepartment of Breast Surgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, People's Republic of China.ORCID 0000-0001-9435-152X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epithelial-myoepithelial carcinoma (EMC) of the breast is a rare biphasic tumor composed of intermixed malignant epithelial and myoepithelial components. Breast epithelial myoepithelial carcinoma lacks therapeutic strategies due to its rarity, and currently local treatment is still the main treatment. Herein we report an epithelial-myoepithelial carcinoma of the breast in a 33-year-old woman undergoing breast conserving surgery, sentinel lymph node biopsy, adjuvant chemotherapy and radiotherapy, with rapid liver and lung metastasis. After radiofrequency ablation therapy for metastatic lesions, vinorelbine plus cisplatin and TROP2 antibody-drug conjugate (ADC) treatment were given successively. After a brief improvement, drug resistance developed and the disease progressed. The patient died with the PFS 5.6 months.

Indexed as

breast cancerepithelial-myoepithelial carcinomamalignant epithelial myoepithelial carcinomatreatmentTROP2 antibody-drug conjugate

Identifiers

PMID40963786
PMCPMC12439690

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.